Steven Goldman (scientist) explained

Steven A. Goldman is an American physician-scientist. His research focuses on the use of stem and progenitor cells for the treatment of neurodegenerative disorders such as Huntington's Disease, as well as for the treatment of glial diseases such as the pediatric leukodystrophies and multiple sclerosis.

Goldman serves as Professor of Neuroscience and Neurology at the University of Rochester and holds a dual appointment at the University of Copenhagen. At both institutions, he serves as a co-director for the Centers of Basic and Translational Neuroscience.[1] Goldman is a graduate of the University of Pennsylvania, with degrees in both Biology and Psychology. He obtained his PhD with Fernando Nottebohm at the Rockefeller University in 1983, and his Medical Degree from Cornell University in 1984. Goldman has authored over 250 scientific articles.[2]

Goldman is the founder of Oscine Therapeutics, a biotechnology company for creating and delivering engineered cells to patients.[3] Goldman is the Senior VP, Head of CNS Therapy for Sana Biotechology. [4]

Publications

His most cited publications are:[5]

Notes and References

  1. Web site: CHDI Foundation Award to Advance Research in Huntington's Disease . 26 July 2019.
  2. Web site: Steven A. Goldman - Biography . May 14, 2023.
  3. Web site: New Funding Boosts URMC Biotech Start-Up for Neurological Disorders . 26 July 2019.
  4. Web site: URMC Partners with Sana Biotechnology to Advance Cell-based Therapies in Neurological Disorders . 2023-05-16 . URMC Newsroom . en-us.
  5. Web site: Google scholar author page. Jan 9, 2021.